Barriers to Timely Intramuscular Epinephrine Administration for Anaphylaxis in Emergency Departments: A Systematic Review

Authors

  • Maqdad Himeed M Al Saif B.Med Sc. M.D. Emergency Medicine resident -Saudi board emergency medicine, King Faisal Specialist Hospital and Research Center, MBC 62, PO Box 3354, Riyadh 11211, Saudi Arabia , ORCID: 0009-0009-9402-0160 Author
  • Muhammad Nauman Qureshi Consultant, Emergency Medicine, King Faisal Specialist Hospital and Research Center, MBC 62, PO Box 3354, Riyadh 11211, Saudi Arabia Author

DOI:

https://doi.org/10.65759/0nm5ww31

Keywords:

Anaphylaxis, Epinephrine, Intramuscular Injection, Emergency Department, Barriers

Abstract

Background: Anaphylaxis is a life-threatening emergency which requires prompt intramuscular epinephrine administration and its use in emergency care still below guideline recommendations. Methods: PubMed, Web of Science, and Scopus were systematically searched for original studies examining barriers to timely intramuscular epinephrine administration in emergency departments and acute care settings. Two reviewers independently screened records, extracted data, and assessed risk of bias using tools appropriate to each study design: the JBI Checklist, NOS, RoB 2, MMAT, and ROBINS-I. Results were synthesized narratively. Results: Twenty-three studies were included: 11 physician knowledge surveys, 11 patient cohort studies, and one simulation study. Clinician barriers included difficulty recognizing anaphylaxis, errors in dose and route selection, and concerns about adverse effects. Older age and the absence of cutaneous symptoms were associated with lower rates of epinephrine administration. Reported organizational barriers included inadequate training, prolonged observation protocols, and deficiencies in discharge practices. Clinicians often reserved epinephrine for severe reactions, contrary to recommendations for its use in all cases of anaphylaxis. Intramuscular administration rates ranged from 16.9% to 60.8%, with treatment omitted in more than 40% of patients in most cohorts. Conclusion: Barriers to timely intramuscular epinephrine administration involve clinical recognition, treatment decisions, patient characteristics, and care procedures. Strategies to reduce delays and omissions should combine targeted education, clinical pathways, and changes to emergency care systems.

References

Cardona V. Overview of allergic disease: Anaphylaxis–WAO White Book on Allergy 2026–2.11. The World Allergy Organization Journal. 2026 Mar 11;19(3):101338.

Ehrhard S, Eyb V, Gautschi D, Schauber SK, Ricklin ME, Klukowska-Roetzler J, Exadaktylos AK, Helbling A. Anaphylaxis in a Swiss university emergency department: clinical characteristics and supposed triggers. Allergy, Asthma & Clinical Immunology. 2024 May 31;20(1):35.

Wyss KJ, Sorensen DM, Winograd SM. Evaluation and Management of Anaphylaxis in the Emergency Department. Emergency Medicine Reports. 2024 Nov 15;45(22):1.

Aytekin ES, Şirin S, Nalbant EK, Ata N, Sertcelik A, Ülgü MM, Birinci Ş, Harmancı K, Akelma Z. Changes in anaphylaxis trends and characteristics in emergency department admissions in Türkiye: From 2015 to 2021 based on the Ministry of Health database. World Allergy Organization Journal. 2025 Jan 1;18(1):101019.

Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. Journal of asthma and allergy. 2018 Jun 20:143-51.

Patel VK. An Overview of Anaphylaxis and the Importance of Speedy Delivery. Patient Care (Online). 2025 Jul 8.

Lieberman PL. Recognition and first-line treatment of anaphylaxis. The American journal of medicine. 2014 Jan 1;127(1):S6-11.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021 Mar 29;372.

Barker TH, Hasanoff S, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, Klugar M, Tufanaru C, Moola S, Liu XL, Munn Z. The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studies. JBI Evidence Synthesis. 2026 Mar 1;24(3):401-8.

Peterson J, Welch V, Losos M, Tugwell PJ. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2011;2(1):1-2.

Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: a revised tool for assessing risk of bias in randomised trials. The Bmj. 2019 Aug 28;366:l4898.

Hong QN, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon MP, Griffiths F, Nicolau B, O'Cathain A, Rousseau MC. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. bmj. 2016 Oct 12;355.

Almarri D, Badghaish F, Albaiji D, Alamri A, Alghamdi R, Alghamdi R, Alkhadra F, Maghraby N. Level of awareness of certified non-critical care physicians in diagnosing, managing, and disposing anaphylactic cases. Medical Archives. 2024;78(1):44.

Yildiz M, Genc AC, Zafer E, Özdemir Ö. Knowledge, practices and preparedness in anaphylaxis management among primary care physicians in Türkiye: A nationwide cross-sectional study. Revue Française d'Allergologie. 2026 Jan 1;66(1):104623.

Campbell RL, Bellolio MF, Knutson BD, Bellamkonda VR, Fedko MG, Nestler DM, Hess EP. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. The Journal of Allergy and Clinical Immunology: In Practice. 2015 Jan 1;3(1):76-80.

Nduwimana MJ, Liu SW, Goldberg EM, Bellolio F, Mullan AF, Wilson R, Campbell RL. Characteristics and outcomes of anaphylaxis in emergency department visits among older adults. The Journal of Allergy and Clinical Immunology: In Practice. 2025 Apr 22.

Khalaf R, Saleem R, Prosty C, McCusker C, Bretholz A, Kaouache M, Clarke AE, Morris J, Lim R, Chan ES, Goldman RD. Clinical presentation, triggers, comorbidities, and management of anaphylaxis in the elderly: a cross-sectional study. International Archives of Allergy and Immunology. 2026 Jul 16;187(8):801-8.

Miles LM, Ratnarajah K, Gabrielli S, Abrams EM, Protudjer JL, Bégin P, Chan ES, Upton J, Waserman S, Watson W, Gerdts J. Community use of epinephrine for the treatment of anaphylaxis: a review and meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2021 Jun 1;9(6):2321-33.

Kartha N, Redmond M, Mason AE, Roth K, Scherzer R, Schneider E, Strothman K. Pathway to Safety: Improving Management of Anaphylaxis Across a Medical Center. Journal of Allergy and Clinical Immunology. 2026 Feb 1;157(2):AB205.

Acquisto NM, Bodkin RP, Vabishchevich Y, Falkowski MW, Tuttle SC, Jones C, Weis E, Bingemann TA. Epinephrine autoinjector prescribing following anaphylaxis presentation to the emergency department. InAllergy and Asthma Proceedings 2023 Jul 1 (Vol. 44, No. 4, pp. 283-290). OceanSide Publications, Inc.

Downloads

Additional Files

Published

2026-10-05